Financial

· 2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of 7.1%* and adjusted operational growth of 7.3%* · 2020 Full-Year Sales of $82.6 Billion reflecting growth of 0.6%, operational growth of 1.2%* and adjusted operational growth of 1.5%* · 2020 Fourth-Quarter EPS of $0.65 decreased 56.7%; adjusted EPS of $1.86 decreased 1.1%* · 2020 Full-Year EPS of $5.51 decreased 2.1%; adjusted EPS of $8.03 decreased 7.5%* · Company provides 2021 guidance of adjusted operational sales growth of 8.8%* and adjusted operational EPS growth of 16.4%*

Updated amivantamab data from the Phase 1 CHRYSALIS study and new data characterizing the high unmet need among patients with non-small cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations to be presented

· Sales of $21.1 billion reflecting an overall and operational increase of 1.7%*, and adjusted operational increase of 2.0%* despite the estimated negative impact of the COVID-19 pandemic · EPS of $1.33 increased 101.5%; adjusted EPS of $2.20 increased 3.8%* · Company increasing guidance for Full Year Reported Sales by $1.0 billion and Adjusted EPS by $0.15 driven by the strength of the recovery and strong underlying business fundamentals